Sargent Investment Group LLC recently announced the acquisition of new stake in Antares Pharma Inc. (NASDAQ:ATRS). The institutional investor has increased its shareholding in the Healthcare company by 12.43% to 4.6 million shares with purchase of 0.51 million shares. This fresh investment now brings its stake to 2.78% valued currently at $13.2 million. In addition, Geode Capital Management LLC raised its holdings by 0.17 million to 2.29 million shares. And Two Sigma Advisers LP has lifted its position by 12.89% or 0.18 million shares – to 1.57 million shares.
With over 0.85 million Antares Pharma Inc. (ATRS) shares trading Monday and a closing price of $2.66 on the day, the dollar volume was approximately $2.27 million. The shares have shown a negative weekly performance of -5.00% and its price on 07/13/20 gained nearly 2.31%. Currently, there are 165.43M common shares owned by the public and among those 153.10M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for ATRS have a consensus price objective of $6.25. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $4.50 should the stock experience a downside. Incidentally, analysts’ outlook for the Antares Pharma Inc. stock is 1.50 for the next 12 months. But an upside of 66.75% will see the stock hit the forecast high price target while mean target price for the stock is $6.50.
Insiders at the company have transacted a total of 59 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 30 of these insider trades were purchases, accounting for 2,254,320 shares. Insider sales of the common stock occurred on 29 occasions, with total insider shares sold totaling 1,364,116 shares.
The top 3 mutual fund holders in Antares Pharma Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 4.13 million shares of the company’s stock, all valued at over $11.85 million. iShares Russell 2000 ETF bought 33655.0 shares to see its total holdings expand to 3.37 million shares valued at over $9.67 million and representing 2.04% of the shares outstanding. Vanguard Extended Market Index Fu bought 12547.0 shares to bring its total holdings to over 2.26 million shares at a value of $6.48 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.36% of the shares outstanding.
Shares of Antares Pharma Inc. (NASDAQ: ATRS) opened at $2.6126, up $0.01 from a prior closing price of $2.60. However, the script later closed the day at $2.66, up 2.31%. The company’s stock has a 5-day price change of -5.00% and 0.00% over the past three months. ATRS shares are trading -43.40% year to date (YTD), with the 12-month market performance down to -11.92% lower. It has a 12-month low price of $1.60 and touched a high of $5.13 over the same period. Currently, 0.85 million shares have been traded, compared to an average intraday trading volume of 1.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.39%, -6.05%, and -21.91% respectively.
Institutional ownership of Antares Pharma Inc. (NASDAQ: ATRS) shares accounts for 43.30% of the company’s 165.43M shares outstanding. Mutual fund holders own 19.67%, while other institutional holders and individual stakeholders account for 25.20% and 15.89% respectively.
It has a market capitalization of $436.96M and a beta (3y monthly) value of 1.34. The stock’s trailing 12-month PE ratio is 380.00, while the earnings-per-share (ttm) stands at $0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.60% over the week and 4.85% over the month.
Analysts forecast that Antares Pharma Inc. (ATRS) will achieve an EPS of $0 for the current quarter, $0.01 for the next quarter and $0.24 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.03 while analysts give the company a high EPS estimate of $0.02. Comparatively, EPS for the current quarter was -$0.01 a year ago. Earnings per share for the fiscal year are expected to increase by 69.90%, and 1100.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Antares Pharma Inc. (ATRS) as a “Strong Buy” at a consensus score of 1.50. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ATRS, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on October 23, 2017, with the firm’s price target at $5-$3.50. H.C. Wainwright coverage for the Antares Pharma Inc. (ATRS) stock in a research note released on June 23, 2017 offered a Buy rating with a price target of $5. Raymond James was of a view on April 21, 2017 that the stock is Strong Buy, while Jefferies gave the stock Buy rating on May 28, 2015, issuing a price target of $5. Piper Jaffray on their part issued Overweight rating on May 18, 2015.